文献速递创面修复

慢性创面细胞疗法的临床研究综述

Cell-Based Therapies for Chronic Wounds Tested in Clinical Studies: Review.
PubMed 文献 · Ann Plast Surg · 2019-01-01

该综述通过PubMed和ClinicalTrials.gov检索分析51篇细胞疗法治疗慢性创面的临床研究,涵盖角质形成细胞、成纤维细胞、骨髓来源细胞及脂肪组织细胞。细胞疗法有望改善创面愈合且避免大型手术和供区并发症,但缺乏患者年龄、健康状况及合并症对疗效影响的指南,仍需多中心对照研究评估剂量反应和细胞来源反应。

要点

  • 细胞疗法可促进慢性创面愈合,避免大型手术和供区并发症
  • 缺乏患者年龄、健康状况及合并症影响疗效的指南
  • 需多中心对照研究评估剂量反应和细胞来源反应

核心结论

  • 细胞疗法在慢性创面治疗中具有改善愈合的潜力,可避免大型手术和供区并发症。
  • 目前仍缺乏多中心对照研究评估剂量反应和细胞来源对慢性创面愈合疗效的影响。

研究设计与样本

  • 综述通过PubMed和ClinicalTrials.gov检索分析细胞疗法治疗慢性创面的可用数据。
  • 分析纳入51篇文章,评估角质形成细胞(10篇)、成纤维细胞(7篇)、角质形成细胞和成纤维细胞(10篇)、骨髓来源细胞(20篇)及脂肪组织细胞(4篇)。
  • 纳入目前市场上可用的细胞产品(Dermagraft、EpiDex、Apligraf和HP802-247)的研究,多数报告为成纤维细胞和角质形成细胞研究。

主要发现

  • 细胞疗法在避免大型手术和供区并发症的情况下具有改善创面愈合的很大潜力。
  • 缺乏指南说明患者年龄、一般健康状况及不同疾病共存如何影响这些疗法的成功率。
  • 需要进一步研究确定移植细胞的命运及获得最佳效果和结局所需的细胞数量。

临床怎么用

  • 细胞疗法可作为慢性创面治疗的潜在选择,避免大型手术和供区并发症。
  • 临床应用中需考虑患者年龄、一般健康状况及合并疾病对细胞疗法成功率的影响。

局限性

  • 缺乏关于患者年龄、一般健康状况及合并疾病如何影响细胞疗法成功率的指南。
  • 移植细胞的命运及获得最佳效果所需的细胞数量尚不明确。
  • 需要多中心对照研究评估剂量反应和细胞来源反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Transplantation of the keratinocytes, fibroblasts, bone marrow, and adipose tissue-derived mesenchymal stem cells may improve chronic wound healing by delivery of different cytokines, chemokines, and growth factors, which play an essential role in wound healing. The purposes of this review were to check which cell lines are potentially beneficial in enhancement of wound healing and to describe the safety and efficacy of cell therapies in the clinical treatment of chronic wounds, as well as to summarize the pertinent literature and research progress in this field. METHODS: PubMed search engine and ClinicalTrials.gov were used to analyze the available data on cell therapies applied in treatment of chronic wound. The analysis included 51 articles, assessing the use of keratinocytes (10), fibroblasts (7), keratinocytes and fibroblasts (10), bone marrow-derived cells (20), and adipose tissue cells (4). Studies on the cell-based products that are currently available on the market (Dermagraft, EpiDex, Apligraf, and HP802-247) were also included, with majority of reports found on fibroblasts and keratinocytes studies. RESULTS: Cell-based therapies have a great potential to improve wound healing without major surgical procedures and donor-site morbidity. There is, however, a lack of guidelines on how the age of the patients, the general health conditions, and the coexistence of different diseases may affect the success of these therapies. Further studies are needed to determine the fate of transplanted cells and the number of cells required to obtain optimal effects and outcomes. CONCLUSIONS: Despite many promising clinical trials on application of various stem cell-based therapies for treatment of chronic wounds, there is still a need for multicenter comparative studies assessing the dose response and the cell source response on the efficacy of chronic wound healing.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Domaszewska-Szostek A, Krzyżanowska M, Siemionow M, et al. Cell-Based Therapies for Chronic Wounds Tested in Clinical Studies: Review. Ann Plast Surg. 2019. PMID: 31335465. doi:10.1097/SAP.0000000000001947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。